CBD is on a Roll, but the FDA is Hitting the Brakes
Charles Feldmann
As the U.S. market for CBD continues to skyrocket and companies competing in the cannabis space become more developed, they are being held back by the slow federal regulatory response at the Food and Drug Administration. On Monday, July 22, the U.S. Food and Drug Administration sent a letter to Curaleaf Holdings CEO Joseph Lusardi warning that the ...